Trade Mark Journal No.2026/027 3 July 2026

UK00004404632 19 June 2026 (5,42)

VASQUE BIO

International priority date claimed: 4 March 2026 (United States of America) (99683475)

Class 5: Pharmaceutical preparations for the treatment of vascular malformations; pharmaceutical preparations for the prevention and treatment of vascular system related diseases and disorders; pharmaceutical preparations for the treatment of autoimmune, cardiovascular, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, respiratory, and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, hormonal disorders, skin disorders, arthritis, cancer, cachexia, hypertension, migraine, pain, stroke, obesity, and diabetes.
Class 42: Pharmaceutical drug development services; scientific research and development; providing support to the pharmaceutical, biotechnology, and medical industries in the form of research services, namely, clinical trials associated with drug development and medical and scientific research services.

Vasque Bio, Inc.

Representative: Carpmaels & Ransford LLP